The designation follows Phase III HARMONi-GI1 results showing significantly improved overall survival versus durvalumab plus ...

Part of Phase III of the National Precision Medicine programme, the study will connect genomic and health data from nearly ...

The National Comprehensive Cancer Network® (NCCN®) announced the signing of a new agreement with the Viet Nam National Cancer ...

Abbott will commercialise Plosbrio®, a second brand of Ozempic® developed and manufactured by Novo, in Singapore and other ...

India and China split the year's export record between them, nine decisions to eight. Korea, the country that taught the region how to sell biosimilars to the West, added no new molecule to either ...

Strategic collaboration aims to accelerate biomarker development, streamline global clinical trials and expand precision medicine capabilities, with a focus on integrating China into multinational ...

Figure 1. Ownership flow for the 21 APAC-origin ADCs in Phase 3 or registrational trials. Left: originator. Right: holder of ...

ASKA gains exclusive Japanese rights to MHB018A, with Minghui receiving $110 million upfront and eligibility for up to $330 ...

Differentia Bio, a developer of AI-powered human disease digital twins, announced that therapeutic mechanisms identified by ...

Mr Ng Tian Chong, Chief Executive Officer, Singtel Singapore; Professor Yeoh Khay Guan, Chief Executive, NUHS; and Mr Daniel ...

Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acquisition of a specialized clinical ...

Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced a ...